ASTELLAS PHARMA UNSP.ADR Asset Resilience Ratio
ASTELLAS PHARMA UNSP.ADR asset resilience ratio. ASTELLAS PHARMA UNSP.ADR (YPHA) has an Asset Resilience Ratio of 0.90% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of ASTELLAS PHARMA UNSP.ADR to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ASTELLAS PHARMA UNSP.ADR (2022–2025)
Asset resilience ratio of ASTELLAS PHARMA UNSP.ADR from 2022 to 2025. This chart shows how ASTELLAS PHARMA UNSP.ADR's Asset Resilience Ratio has changed over time. Read ASTELLAS PHARMA UNSP.ADR debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ASTELLAS PHARMA UNSP.ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see YPHA current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €29.94 Billion | 0.9% |
| Total Liquid Assets | €29.94 Billion | 0.90% |
Asset Resilience Insights
- Limited Liquidity: ASTELLAS PHARMA UNSP.ADR maintains only 0.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ASTELLAS PHARMA UNSP.ADR Industry Peers by Asset Resilience Ratio
Compare ASTELLAS PHARMA UNSP.ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
ASTELLAS PHARMA UNSP.ADR Asset Resilience Ratio by Year (2022–2025)
ASTELLAS PHARMA UNSP.ADR asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for ASTELLAS PHARMA UNSP.ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.90% | €29.94 Billion ≈ $35.00 Billion |
€3.34 Trillion ≈ $3.90 Trillion |
+0.09pp |
| 2024-03-31 | 0.81% | €28.78 Billion ≈ $33.65 Billion |
€3.57 Trillion ≈ $4.17 Trillion |
+0.00pp |
| 2023-03-31 | 0.81% | €19.78 Billion ≈ $23.13 Billion |
€2.46 Trillion ≈ $2.87 Trillion |
-0.11pp |
| 2022-03-31 | 0.91% | €21.30 Billion ≈ $24.90 Billion |
€2.33 Trillion ≈ $2.73 Trillion |
-- |
About ASTELLAS PHARMA UNSP.ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms… Read more